Eutilex Co.,Ltd. Logo

Eutilex Co.,Ltd.

Develops T-cell and antibody immunotherapies for cancer and autoimmune diseases.

263050 | KO

Overview

Corporate Details

ISIN(s):
KR7263050007
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 58 408호 (가산동, 에이스한솔타워), 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of breakthrough immunotherapeutics for incurable diseases, particularly cancer and autoimmune disorders. The company's core activities are centered around three proprietary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Its pipeline includes adoptive T-cell therapies, such as 4-1BB cytotoxic T-lymphocytes (CTL), and immunomodulatory antibody therapeutics designed to act as immune checkpoint activators, stimulating T-cells to enhance anti-tumor immune responses. Eutilex's approach is based on selecting novel targets that effectively enhance or suppress human immune functions to treat diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.0 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.0 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.3 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.3 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 116.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 959.6 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.7 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 112.9 KB
2025-05-08 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 10.1 KB

Automate Your Workflow. Get a real-time feed of all Eutilex Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Eutilex Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Eutilex Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D

Talk to a Data Expert

Have a question? We'll get back to you promptly.